1982P Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)

This article has no abstract
Epistemonikos ID: c8ba2b5a58495c3a98255cd9fc9a132060f26336
First added on: Feb 19, 2025